Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8565784 | 1.00 | CYP19A1 (0.36) | CYP19A1DAOMAOAMAOBGRM1 | |
| SCHEMBL12289430 | 1.00 | CYP19A1 (0.36) | CYP19A1DAOMAOAMAOBGRM1 | |
| SCHEMBL10706120 | 0.93 | CYP19A1 (0.33) | CYP19A1DAOMAOAMAOB | |
| SCHEMBL10676307 | 0.93 | DAO (0.40) | CYP19A1DAOMAOAMAOB | |
| SCHEMBL10017472 | 0.93 | CYP19A1 (0.33) | CYP19A1DAOMAOAMAOB | |
| SCHEMBL10485940 | 0.93 | CYP19A1 (0.33) | CYP19A1DAOMAOAMAOB | |
| SCHEMBL10676302 | 0.93 | DAO (0.40) | CYP19A1DAOMAOAMAOB | |
| SCHEMBL23133729 | 0.84 | — | — | |
| SCHEMBL21946982 | 0.84 | — | — | |
| SCHEMBL21961817 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328227-A1 | NUCLEOSIDE COMPOUND AND APPLICATION THEREOF IN THE TREATMENT OF FELINE INFECTIOUS PERITONITIS | Vigonvita Life Sciences Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-11874434-B2 | Ophthalmic devices comprising photochromic materials with reactive substituents | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023111996-A1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE HOLDING, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230150933-A1 | BROAD SPECTRUM ANTIVIRALS AGAINST CORONAVIRUS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2023-05-18 | — | — | US | disclosed |
| US-20070254916-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | MJALLI ADNAN M | 2007-11-01 | — | — | US | disclosed |
| US-7208601-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, LLC | 2007-04-24 | — | — | US | disclosed |
| US-7208601-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, LLC | 2007-04-24 | — | — | US | disclosed |
| WO-2007022493-A2 | LIGAND CONJUGATES OF VINCA ALKALOIDS, ANALOGS, AND DERIVATIVES | ENDOCYTE, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006117548-A1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| US-20050171148-A1 | Aryl and heteroaryl compounds, compositions, methods of use | TRANSTECH PHARMA, LLC | 2005-08-04 | — | — | US | disclosed |
| US-20050171148-A1 | Aryl and heteroaryl compounds, compositions, methods of use | TRANSTECH PHARMA, LLC | 2005-08-04 | — | — | US | disclosed |
| WO-2005012312-A1 | NOVEL CYANO THIAZOLIDES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012308-A1 | NOVEL CYANOPYRROLIDIDES, METHODS FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-10 | — | — | WO | disclosed |
| WO-2003082350-A2 | RADIOLABELLED QUINOLINE AND QUINOLINONE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CYP19A1 3787/4885DAO 1864/4885MAOA 4419/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | CYP19A1 3515/4885DAO 843/4885MAOA 2553/4885 |
| US-20070254916-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F9, F3 | CYP19A1 226/4885DAO 188/4885MAOA 102/4885 |
| US-20230150933-A1 | BROAD SPECTRUM ANTIVIRALS AGAINST CORONAVIRUS | SARS1, ZC3HAV1, POLL | CYP19A1 3194/4885DAO 860/4885MAOA 2572/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CYP19A1 3787/4885DAO 1864/4885MAOA 4419/4885 |
| US-20050171148-A1 | Aryl and heteroaryl compounds, compositions, methods of use | TFPI, F3, F2 | CYP19A1 248/4885DAO 214/4885MAOA 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.